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ABSTRACT 
3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is a major endogenous ligand found 
in the human serum albumin (HSA) of renal failure patients. It gets accumulated in the HSA and 
its concentration in sera of patients may reflect the chronicity of renal failure [1-4]. It is 
considered uremic toxin due to its damaging effect to the renal cells. The high concentrations of 
CMPF inhibit the binding of other l igands  to  HSA.  Removal of CMPF is difficult through 
conventional hemodialysis due to i t s  strong binding affinity. We hypothesized that the 
competitive inhibition may be helpful in removal of CMPF binding to HSA. A compound with 
higher HSA binding affinity than CMPF could be useful to prevent CMPF from binding so that 
CMPF could be excreted by the body through the urine. We studied an active compound 
dihydrothymoquinone/ dithymoquinone (DTQ) found in black cumin seed (Nigella sativa), 
which has higher binding affinity for HSA.  Molecular docking simulations were performed to 
find the binding affinity of CMPF and DTQ with HSA. DTQ was found to have higher binding 
affinity possessing more interactions with the binding residues than the CMPF. We studied the 
binding pocket flexibility of CMPF and DTQ to analyze the binding abilities of both the 
compounds. We have also predicted the ADME properties for DTQ which shows higher 
lipophilicity, higher gastrointestinal (GI) absorption, and blood-brain barrier (BBB) permeability. 
We discovered that DTQ has potential to act as an inhibitor of CMPF and can be considered as 
a candidate for the formation of the therapeutic drug against CMPF. 
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INTRODUCTION 
CMPF has been linked to the acute renal failure [1-3,5]. CMPF is a major endogenous toxin 
retained in uremic serum and major drug-binding inhibitor [6]. The accumulation of CMPF 
is caused by binding of CMPF to HSA, which cannot be removed through conventional 
hemodialysis [7]. Currently, there is no known inhibitor for CMPF which can reduce its 
accumulation. 
Our Hypothesis 
CMPF accumulation is due to its high binding affinity towards HSA among uremic toxins [8-
10]. We hypothesized that another compound with a higher binding affinity towards HSA than 
CMPF should be able to bind with HSA. Thus, effectively blocking CMPF from binding. This 
could have beneficial effects on human health apart from the effects on kidneys. The binding 
of CMPF could be reduced leading to the decreased chances of acute renal failure. Assuming 
this, we hypothetically considered a compound which has been earlier proved to be beneficial for 
human health, such as cancer, tumor, and more [11-17]. This compound is dithymoquinone 
(DTQ), one of the active compounds found in black cumin seed (Nigella sativa), which is 
well known for its positive effects on human in various conditions such as tumor, cancer, 
clearance of hepato-renal toxicity, diabetes, [8-18].and found to possess relatively higher 
binding affinity than CMPFWe predicted the inhibitory effect of DTQ against CMPF using in 
silico docking performed by AutoDock tools [19]. In order to determine the capability of DTQ 
as the potential drug candidate against CMPF, we predicted its ADME properties using 
SwissADME [20]. The crucial role of CMPF in renal failure, binding with HSA, and DTQ 
is discussed in detail in the following sections. 
HSA- receptor for endogenous substances and drugs 
HSA is an abundant plasma protein that belongs to a multigene family of proteins including α-
fetoprotein, vitamin-D binding protein, and human group specific component [21]. HSA binds to 
a wide range of drugs and/ or endogenous ligands including bilirubin, thyroxine, non-esterified 
fatty acids, and hemin [21], all of them being lipophilic, acidic compounds, in multiple sites [22-
27]. HSA protein consists of 585 amino acids with 17 disulphide bridges, one tryptophan residue 
(Trp 214), and a single free-thiol (Cys 34) [28]. According to Sudlow et al., (1975) [29], there 
are two binding sites in HSA: Site I and Site II. He & Carter (1992) [28] observed the binding 
pockets of HSA lying in two subdomains: IIA and IIIA, which were the same sites but they 
used different nomenclature to denote them. HSA is considered a silent receptor for drugs [30] 
because it serves as a repository for a wide variety of compounds as the negative charge on HSA 
facilitates the electrostatic binding of various ligands and acts as a depot and carrier for many 
drug compounds [31-34]. Due to the presence of limited number of high- affinity binding 
sites in HSA, detailed molecular information about these sites could be helpful in studying the 
effects of other drugs or ligands and the structural information of both low- and high- affinity 
binding sites is useful in designing new drugs with the aim either avoiding binding to HSA or to 
make use of its functions [35]. 
CMPF is a metabolite of F-acids [36-40] which was first detected in human urine [37] and then 
later in human blood [38]. CMPF is considered as one of the major drug- binding inhibitor [1,6,41-
43]. The drug-binding effect observed in vivo that the CMPF levels rise in kidney patients are due 
to the specific steric blocking of drug site 1 by this compound [43,44]. Sakai et al., (1995) [44] 
studied the interactions of CMPF in comparison of other three uremic toxins: indoxyl sulphate, 
indole acetic acid, and hippuric acid using fluorescent probe displacement, ultrafiltration, and 
equilibrium dialysis. The results showed that CMPF had the highest binding affinity (10-7 M-1) 
among the three uremic toxins. As compared with the other uremic toxins, CMPF consists of 
least rate of elimination and the most potent inhibitor [10,44-47]. Several studies have 
demonstrated that uremic toxins are involved in the production of reactive oxygen species 
(ROS) [48-50]. In a study conducted by Miyamoto et al., (2012) [50], it was shown that 
CMPF induces the renal cell damage by enhancing the production of ROS in the presence of 
Angiotensin-II (A-II), which is an inducer of oxygen free radicals. Also, in the presence of iron, 
CMPF and A-II induce the Fenton's reaction leading to an increase in ROS production. The 
subsequent interaction of CMPF with dissolved oxygen leads to the overproduction of oxygen 
free radicals. 
All the experiments mentioned above are sufficient enough to prove the damaging role of 
CMPF in renal failure because they have used reliable techniques (GC-MS, HPLC, etc.) to study 
the levels of CMPF in uremic/ dialyzed patients. On the basis of these findings, we can conclude 
that CMPF is responsible for renal failure by getting accumulated in the renal cells and due to 
its prooxidant nature, it increases the ROS production in the endothelial cells, which ultimately 
leads to the renal cellular damage. Another role of CMPF in renal damage which may not be 
denied is its ability to bind very strongly to HSA making itself a strong potent inhibitor resulting 
in accumulation and ultimately to renal failure. It may be of great importance to remove 
accumulated CMPF from HSA to prevent renal failure due to its inhibiting properties. Other 
compounds cannot easily replace CMPF which has a higher binding affinity. Addressing this 
major problem, we have shown that, DTQ - a compound which is already well- known for its 
beneficial effects on human health, and an active component of black cumin seed (Nigella 
sativa) has higher binding affinity towards HSA than the CMPF and higher lipophilicity due to 
which it may be proven as a potential drug candidate in curing renal failure caused by CMPF.  
Black Cumin Seed (Nigella sativa) 
CMPF being the major drug-binding inhibitor, its binding with HSA could be restricted using any 
other compound with higher binding affinity and high therapeutic efficacy. Black cumin seed 
(Nigella sativa) has been known for its therapeutic efficiencies since many centuries. It has 
been referred in Islamic tradition as having healing powers [51]. It is a spice grown in 
Mediterranean region and in Western Asian countries such as India, Afghanistan, and Pakistan. 
The historical references to the seeds are also found in some of the oldest religious medical 
texts such as it is referred by Hippocrates and Dioscorides as ‘Melanthion’, the Bible describes it 
as the curative black cumin (Isaiah 28:25, 27 NKJV), and according to hadith, Islamic messenger 
Prophet Muhammad (PBUH) said “In the black seed is healing for every disease except death” 
(Sahih Bukhari). 
Black cumin seeds have also been used in traditional medicines for many past years for the 
treatment of a wide range of diseases including a headache, bronchial asthma, infections, 
dysentery, back pain, hypertension, and gastrointestinal problems [52]. The pharmacological 
investigations of black cumin seed extracts have revealed its potential broad spectrum activities 
as antihistaminic [53], antimicrobial [54], anti-diabetic [55], anti-hypertensive [56], 
immunopotentiation [57], and anti-inflammatory [58]. It has also been proved to be consisting 
of anti-tumor [12] and anticancer activities [59-61]. 
DTQ- a solution to CMPF accumulation problem 
The bioactive constituents of the volatile black seed oil were first identified by Al-Dakhakhany 
(1963) [62] showing thymoquinone (TQ) as the most active constituent (about 54%) among the 
others. Later on, other active compounds: DTQ, thymol (THY), and thymohydroquinone (THQ) 
were identified by Ghosheh et al., (1999) [11] using HPLC. TQ (2-isopropyl-5-methyl-
1,4-benzoquinone) has been shown to exhibit anti-inflammatory, anti-oxidant, anti-neoplastic 
activities both in-vivo and in-vitro [63]. DTQ, THY, and THQ are more likely the metabolites 
of TQ as under physiological conditions, TQ gets slowly reduced to DTQ and THY [64]. 
TQ has been shown to possess antioxidant properties through different mechanisms such as it 
inhibits the formation of 5-hydroxyeicosa-tetraenaoic as well as 5-lipoxygenase products [65] 
which are required for the viability of colon cancer cells. Most importantly, in the context of this 
study, TQ has been shown to act as a scavenger to various ROS [66-68]. The molecular surfaces 
of TQ and DTQ possess significant amount of positively charged electron-deficit regions so that 
they may be subjected to nucleophilic attacks by glutathione and nucleotide bases in DNA, 
thereby, causing cellular toxicity due to the depletion of glutathione and damage of DNA due to 
the oxidation of nucleotide bases. 
Badary et al., (1997) [69] studied the effects of TQ on cisplatin-induced nephrotoxicity and 
concluded that TQ ameliorates the nephrotoxicity in rodents and induce the anti-tumor activity 
of cisplatin. Due to the antioxidative and anti-inflammatory properties of TQ, it acts against 
renal injuries [15]. Fouda et al., (2008) [70] studied the effects of TQ on renal oxidative damage 
and proliferative response induced by mercuric chloride in rats and based on their results it was 
concluded that it may be a clinically valuable agent in the prevention of acute renal failure 
caused by inorganic mercury intoxication. Similarly, Hamed et al., (2013) [17] studied the 
effects of black cumin seed oil on hepato-renal injury induced by bromobenzene exposure. 
They concluded that the treatment with black seed oil significantly enhanced the hepato-renal 
protection mechanism, reduced disease complications, and delayed its progression [17]. 
All these investigations done earlier supports that renal failure/damage can be 
prevented/treated with black cumin seed due to the presence of anti-oxidative component TQ 
and/ DTQ. TQ and DTQ both are similar in a way that they both have oxygen atoms on 1,4- 
positions of the benzene ring (Fig. 1), which contribute to their anti-oxidative properties. In this 
study, we performed docking experiments on HSA with DTQ (having same properties as TQ) 
and HSA with CMPF and found that DTQ was able to bind more effectively than CMPF. 
Therapeutics available for uremic ailments 
Numerous uremic toxins such as indoles and phenols were detected for the first time in uremic 
plasma between the 1940s and 1990s [71-73]. It has been proved that a majority of uremic 
toxins originate endogenously through mammalian metabolism and therefore, it is being 
increasingly recognized that intestinal microbial metabolism has a large effect on mammalian 
blood metabolites resulting in the formation of various uremic toxins such as indoxyl sulphate, 
p-cresol sulphate, etc. [74-76]. CMPF, which is also a uremic toxin, is said to a metabolite of F- 
acids [36-40] and there are still no evidence to locate the place of its metabolization in humans. 
There are two main existing therapeutic approaches to treat ailment caused by uremic toxins: 
1) interventions that modulate bacterial growth such as probiotics, prebiotics, and dietary 
modifications. 2) adsorbents that bind uremic toxins to reduce their absorption by the host. 
Both of these approaches are based on the fact that these uremic toxins are metabolized by the 
gut microbiota, but in the case of CMPF, it is still rendered questionable. However, the 
adsorbent approach is sometimes not helpful in retarding the progression of chronic kidney 
disease, for example, Sevelamer hydrochloride (Renagel; Genzyme, Cambridge, MA, USA) has 
been shown to bind some of the uremic toxins such as indoxyl sulphate (10-15%) and p-cresol 
(40-50%, depending on pH) [77], but it did not result in decreased serum concentrations of 
these uremic toxins in a mouse model of chronic kidney disease. However, the treatment of 
sevelamer in humans for studying the alterations in serum concentrations of microbial 
metabolites remains to be investigated. 
METHODS 
Retrieval of the structures 
The 3D structures of DTQ and CMPF were downloaded from PubChem (PubChem CID: 398941 
and PubChem CID: 123979, respectively). The protein crystal structure of HSA was downloaded 
from Protein Data Bank (PDB ID: 2BXA) [78]. 
Molecular docking simulations 
As revealed by Ghuman et al., (2005) [78], CMPF binds to the Y-150, R-257, H-242, R-222, and 
K-199 in the site I of HSA. Molecular docking simulations were done by AutoDock Vina [19]. 
CMPF and DTQ were docked with HSA by having default x, y, and z coordinates, i.e., 40 for 
each, and the center coordinates were set accordingly. The docking results were analyzed using 
PyMol [79]. 
Binding Analysis 
Some of the factors which were influenced by binding of CMPF and DTQ with HSA were 
analyzed by BINANA software [80]. BINANA (BINding ANAlyzer) is a python-
implemented algorithm to analyze ligand binding. This software analyzes the key binding 
characteristics such as pi-pi interactions, hydrogen bonds, salt bridges, etc. In this study, we 
used BINANA to identify the active-site flexibility of CMPF and DTQ with HSA. The results 
are shown in Table 1. 
ADME properties analysis 
The ADME properties of DTQ were predicted by SwissADME software [20]. The 
ADME properties predicted by the SwissADME include physicochemical properties, 
lipophilicity, water solubility, pharmacokinetics, drug-likeness, and medicinal chemistry. 
These properties are shown in Table 2. 
RESULTS 
Docking simulation results 
Docking results showed that DTQ bound more effectively than CMPF showing the higher 
binding affinity (-8.1 kcal/mol) than the later (-7.0 kcal/mol). DTQ was able to occupy the 
binding pocket more efficiently than the CMPF (Fig. 2A and 2B). Docking simulations of 
CMPF with HSA showed the interaction with four residues of HSA: Y150, K199, R222, and 
R257 having the bond lengths equal to 2.9 A, 3.0 A, 3.0 A, and 3.2 A respectively (Fig. 3A). 
Similarly, DTQ bound with Y150, K199, R222, and R257 residues of HSA having the bond 
lengths equal to 3.0 A, 2.7 A, 3.0 A, and 3.2 A respectively (Fig. 3B). The bond lengths 
formed by DTQ are comparatively smaller than that of CMPF, this is the another parameter to 
support that DTQ is capable of binding more efficiently than CMPF and since the former bound 
at the same position as the later one, we can conclude that DTQ may be a potent inhibitor of CMPF. 
Fig. 2 Binding pocket of HSA A) CMPF B) DTQ. DTQ bind in the same pocket as CMPF in 
HSA and covers the binding site more efficiently than the CMPF. 
Fig. 3 Representing the interaction and bond lengths of A) CMPF and B) DTQ with HSA. 
DTQ showed shorter bond lengths with the interacting residues than that of CMPF. 
Binding Analysis results 
According to Koshland, the active-site residues usually adjust to allow the binding of a specific 
substrate [81]. The induced-fit model assumes that the active site is flexible and changes shape 
to allow the complete binding of a substrate [82], which is a case here for CMPF and DTQ 
binding with HSA. BINANA categorizes each atom into six possible characterizations: alpha‐ 
sidechain, alpha‐backbone, beta‐ sidechain, beta‐ backbone, other‐sidechain, and other‐ 
backbone. The number of close‐ contact receptor atoms falling under each of these six 
categories is tallied as a metric of binding‐site flexibility. According to the predicted results of 
BINANA, DTQ showed more flexibility than CMPF towards the backbone and the side-
chain (Table 1). These results suggest that the binding residues of HSA have to undergo 
more conformational changes for DTQ which may be due to the more complex structure than that 
of CMPF, and it may also contribute to the higher binding affinity of the former than the later. 
Table 1 Binding pocket flexibility properties of CMPF and DTQ. 
Ligand Side-chain/ 
Backbone 
Secondary structure Count 
CMPF Side-chain Alpha 153 
 Backbone Alpha 111 
DTQ Side-chain Alpha 208 
 Backbone Alpha 153 
 Side-chain Other 4 
 
ADME properties 
The ADME properties of DTQ were predicted in order to determine its lipophilicity. Lipophilicity 
is one of the important parameters which is considered for drug candidates metabolism, 
greater the lipophilicity, more is the absorption. The ADME results are shown in Table 2. 
Table 2 ADME properties of CMPF and DTQ predicted by SwissADME. 
ADME properties DTQ 
Molecular weight 328.40 g/mol 
Lipophilicity (WLogP) 2.71 
Consensus Log Po/w 2.62 
Water Solubility (ESOL) -3.05 
GI absorption High 
BBB permeant Yes 
Log Kp (skin permeation) -6.83 cm/s 
Lipinski rule Yes 
Leadlikeness Yes 
Synthetic accessibility  4.65 
 
Lipophilicity is the ability of the compound to dissolve in lipophilic solutions to permeate 
through the various biological membranes. It is measured the distribution of the compound 
between the non-aqueous (octanol) and the aqueous (water) phase, and the result is expressed 
as the logarithm of the concentration ratios termed as logP. A desired logP value is less than 5.0 
[83]. In the case of DTQ, the estimated logP value is 2.62, which shows its higher lipophilicity. 
The BBB permeability is not considered good for the compounds as it may cause other harmful 
effects to the brain, but in the case of black cumin seed, it has been found that it causes beneficial 
neuropsychiatric effects and helps in to improve memory, and mood [84-86]. 
BOILED-Egg results predicted by SwissADME 
Brain Or IntestinaL EstimateD permeation (BOILED-Egg) method predicts an accurate model 
to analyze the gastrointestinal (GI) absorption and blood-brain barrier (BBB) of the candidate 
drugs [87]. It works by calculating the lipophilicity and polarity of the molecules. The BOILED- 
Egg representation of DTQ is shown in Fig. 4. The white region represents the physicochemical 
space of the molecule possessing the highest probability of absorption by the GI tract, whereas 
the yellow region represents the physicochemical space of the molecule having the highest 
probability to permeate the brain. According to the BOILED-Egg representation generated by 
the SwissADME, DTQ has high GI absorption and the BBB permeability (Fig. 4). 
CONCLUSION AND FUTURE DEVELOPMENTS 
In this study we attempted to provide an insight into the role of CMPF in renal failure as implicated 
by many studies since quiet a time. CMPF has been found to be involved in causing type 2 diabetes 
by disrupting the beta-cell function [88-91], but it stands contradictory as some of the research 
does not correlate CMPF with diabetes [92,93] and also due to the lack of evidences CMPF has 
not been positively correlated with diabetes [94]. Therefore, we have addressed only the problem 
of CMPF binding with HSA leading to its accumulation and causing renal failure. According to 
the studies mentioned above, the capability of CMPF to bind strongly with HSA has posed a 
difficult task to remove the accumulated CMPF from the renal tubular cells. In this paper, we have 
proposed a suitable solution for the situation through in silico studies. We conclude that DTQ is 
capable to bind more strongly to HSA than the CMPF and shows inhibitory effects, which requires 
further in vitro studies to elucidate its actual mechanism of inhibition. The past publications 
provide sufficient evidences regarding the health benefits of active components of black cumin 
seed (Nigella sativa), therefore, we can conclude that DTQ possess many health benefits for 
humans due to its capability to bind with HSA more efficiently than CMPF, making it the best 
possible solution for inhibition of CMPF binding to HSA. Also, as CMPF is a strong lipophilic 
uremic solute (Depner, 1981), therefore, we comparatively analyzed the ADME properties of DTQ 
and CMPF in silico. According to the predicted ADME properties, DTQ could be considered as 
the potential drug candidate against the action of CMPF and can be further utilised to make 
therapeutic drugs to treat renal failure caused by the accumulation of CMPF in renal cells. 
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Figure legends 
Fig.1 2D structure of a) TQ b) DTQ 
Fig. 2 Binding pocket of HSA A) CMPF B) DTQ. DTQ bind in the same pocket as CMPF in 
HSA and covers the binding site more efficiently than the CMPF. 
Fig. 3 Representing the interaction and bond lengths of A) CMPF and B) DTQ with HSA. 
DTQ showed shorter bond lengths with the interacting residues than that of CMPF. 
Fig. 4 BOILED-Egg representation of DTQ. Yellow region represents the BBB and the white 
region represents the GI absorption, and red circle represents the molecule (i.e., DTQ). 
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